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0Real-time magnetic resonance imaging (rtMRI) is considered
attractive for guiding transarterial aortic valve implantation
(TAVI). Compared with X-ray fluoroscopy, rtMRI offers unre-
stricted scan plane orientation and an unsurpassed soft-tissue
contrast with simultaneous device visualization, potentially allow-
ing enhanced positioning accuracy together with online monitor-
ing of cardiac function and immediate detection of complications.
Additionally, MRI offers noninvasive assessment of cardiovascular
anatomy and function for preinterventional screening as well as
immediate morphologic and functional assessment of the im-
planted prothesis and may, thus, be envisioned as a single com-
prehensive imaging modality for TAVI.
We, therefore, sought to assess the preclinical feasibility of
entirely rtMRI-guided TAVI in a swine model (female domestic
pigs weighing 70.5 to 86.5 kg) using the original CoreValve
(Medtronic, Minneapolis, Minnesota) prosthesis without altera-
tions in conjunction with a modified, MRI-compatible delivery
device (1).
rtMRI-guided transfemoral (n 2) and transsubclavian (n 6)
TAVI was performed in a 1.5-T whole-body MRI scanner
(Magnetom Avanto, Siemens Healthcare Sector, Erlangen, Ger-
many). Conventional x-ray fluoroscopy and angiography were
performed for comparison. After pre-interventional evaluation
using standard steady-state free-precession imaging with electro-
cardiographic gating and time-resolved retrospective image recon-
struction (cine-TrueFISP retro) (TR, 40 ms; TE, 1.1 ms; flip
angle, 62°; FOV, 380  330 mm2; matrix, 192  168; slice
hickness, 6 mm; bandwidth, 930 Hz/pixel; image acquisition
ime, 15 s for a single slice acquired over 20 phases of the cardiac
-R interval) and electrocardiography-triggered, flow-sensitive,
hase-contrast sequences (TR, 62 ms; TE, 3.5 ms; flip angle, 30°;
OV, 320  220 mm2; matrix, 192  132; bandwidth, 555
Hz/pixel; acquisition time, 1 min 52 s; velocity encoding value, 100
cm/s), TAVI was performed using rtMRI fluoroscopy based on a
commercially available interactive real-time projection reconstruc-
tion TrueFISP sequence with radial k-space filling during free
breathing and without cardiac triggering that was modified to
achieve a frame rate of 7 frames per second (TR, 3.0 ms; TE, 1.5
ms; flip angle, 70°; FOV, 360  360 mm2; matrix, 192  192;
bandwidth, 1530 Hz/pixel; slice thickness, 6 mm). Images were
displayed without delay inside the scanner room and could be
adapted interactively according to the operator’s (P.K.) needs while
the sequence was running. After TAVI, real-time TrueFISP,
cine-TrueFISP retro, and flow-sensitive phase-contrast sequences
were used to verify procedural success. Autopsies were performed
to validate MRI findings.
Three-point localizer sequences allowed for rapid detection (11 
3 min) of all scan planes required for preinterventional evaluation,procedural guidance, and post-procedural validation. High-
resolution TrueFISP retro sequences enabled detailed visualization
of all procedurally relevant anatomic landmarks and allowed
precise measurements (aortic annulus diameter in long axis, 17 
3 mm; aortic arch diameter, 21  4 mm; distance from aortic
annulus to left and right coronary ostium, 9  3 and 10  2 mm;
ccess vessel diameter, 6.9  1.2 mm) in good accordance with
easurements on previous angiographic images (mean error, 0.4
.3 mm; p  NS) and during autopsy (mean error, 0.5  0.2 mm;
p  NS).
Passive device visualization using real-time TrueFISP sequences
provided reliable imaging guidance during TAVI superior to
fluoroscopy. Mild susceptibility artifacts confined to the loaded
stent valve enabled adequate determination of the position of stent
valve and delivery system in relation to the surrounding anatomy
without undue image distortion, allowing a precise, real-time
anatomic orientation during device navigation through the vascu-
lature, aortic valve passage, positioning and deployment of the
prosthesis, and catheter withdrawal.
In 6 of 8 animals, an oversized 26-mm CoreValve prosthesis
was successfully placed across the aortic annulus without disloca-
tion, coronary artery obstruction, or impairment of the mitral
valve, as confirmed by autopsy (rtMRI acquisition time, 4  2
min) (Fig. 1). However, 2 implant failures occurred. The first was
a result of unsuccessful aortic arch passage due to insufficient
support by the initially used MRI-compatible, soft polymer guide-
wire and led to a controlled deployment of the stent valve in the
thoracic aorta, which is sometimes required in clinical application
when the prosthesis dislocates into the ascending aorta during
deployment. As a consequence, we continued our experiments
without guidewire support and focused on the straighter transsub-
clavian access route. The second implant failure occurred due to
perforation of the left ventricular apex caused by the delivery
device, which was inadvertently pushed with too much force, this
complication being immediately detected by rtMRI. Both cases
indicate that rtMRI might improve both precision and safety of
the TAVI procedure.
Postprocedural TrueFISP retro sequences allowed precise struc-
tural evaluation of the procedural result in good accordance with
autopsy findings. Flow-sensitive, electrocardiography-triggered,
phase-contrast sequences with imaging planes placed approximately 1
cm below and above the nitinol stent frame confirmed good systolic
transvalvular blood flow without diastolic regurgitation.
The current study demonstrates the preclinical feasibility of
entirely MRI-guided TAVI. As a single imaging modality, MRI
offered comprehensive diagnostic evaluation of the relevant cardiac
and vascular anatomy for adequate interventional planning, real-
time procedural guidance with excellent anatomic orientation,
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January 10, 2012:192–5immediate evaluation of procedure-related complications, and
post-interventional validation of treatment success with a total
procedure time of 61  13 min. Complementary to reduction of
radiation exposure and nephrotoxic contrast media, rtMRI guid-
ance, therefore, provides clinically relevant advantages over con-
ventional X-ray-fluoroscopy and warrants further attention. These
advantages should encourage future efforts to translate rtMRI-
guided TAVI into clinical application using commercial but
modified or entirely novel devices (2,3) and to overcome remaining
obstacles such as the development of suitable, MRI-compatible
Figure 1 Transsubclavian TAVI
After initial device position was confirmed in parasagittal and axial orientations
using cine-TrueFISP retro sequences (A), the stent valve was deployed step-
wise across the aortic annulus while monitoring with real-time TrueFISP imaging
(B). After implantation, cine-TrueFISP retro sequences were repeated to con-
firm valve positioning (C).guidewires.
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Sprint Fidelis Leads
and Patient Mortality
We read with interest the report of all-cause mortality in patients
with Fidelis leads as compared with those with nonadvisory leads1,641 Quattro patients (Minneapolis, Minnesota) over a mean
follow-up period of 34.4 and 39.9 months, respectively, there was
no difference in adjusted survival rates. The authors contend that
their data support the current manufacturer’s strategy of “contin-
ued clinical follow-up with the addition of the Lead Integrity Alert
(LIA)” and conclude that this “argues against prophylactic removal
of a normally functioning Fidelis lead” (1). In the accompanying
editorial, Faddis (2) states that these data by Morrison et al. (1)
“provide valuable guidance” with respect to lead management
